These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

### Drug Details

<table>
<thead>
<tr>
<th>Company</th>
<th>Business Partner</th>
<th>Drug Name</th>
<th>Generic Name</th>
<th>Unique ID</th>
<th>Indications</th>
<th>Disease</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td></td>
<td>Kaletra</td>
<td>lopinavir/ritonavir</td>
<td>M02-418</td>
<td>HIV</td>
<td>Infection</td>
<td>III</td>
</tr>
</tbody>
</table>

#### Clinical Study

**Protocol No. M02-418.** A Randomized Open-Label Study of 800 mg Lopinavir/200 mg Ritonavir QD in Combination with Tenofovir and Emtricitabine vs. 400 mg Lopinavir/100 mg Ritonavir BID in Combination with Tenofovir and Emtricitabine in HIV-Infected Antiretroviral-Naive Subjects.


Abbott Laboratories (Abbott) will use reasonable efforts to include accurate and up-to-date information, consistent with Abbott policies and procedures, on the ClinicalStudyResults.org web site. However, because, among other reasons, the status of studies often changes, Abbott can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein.

Persons accessing and using information posted by Abbott on the ClinicalStudyResults.org web site do so at their own risk. Abbott disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Abbott shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Abbott on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof.

#### Company Study

No document provided.